Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(21)
PROCEDURE(4)
DRUG(2)
BIOLOGICAL(2)
Biospecimen Collection
4 trials
phase_1phase_2
city-of-hope-medical-center
Bone Marrow Biopsy
3 trials
phase_1phase_2
city-of-hope-medical-center
Computed Tomography
2 trials
phase_1phase_2
city-of-hope-medical-center
Bone Marrow Aspiration
1 trial
phase_2
city-of-hope-medical-center
Copanlisib
1 trial
phase_1
city-of-hope-medical-center
Echocardiography
1 trial
phase_1
city-of-hope-medical-center
Electronic Health Record Review
1 trial
phase_2
city-of-hope-medical-center
Zanubrutinib
1 trial
phase_1
city-of-hope-medical-center

+16 more interventions

24 unique interventions5 categories

Analytics

Trial Phases

Phase 12
Phase 25

Trial Status

Completed1
Recruiting3
Other3

Role Distribution

Principal Investigator7
PI Rate100%

Activity Timeline

Clinical Trials (7)

NCT07218510Phase 2Recruiting
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
PrincipalinvestigatorStart date: 2026-01-07
NCT06735664Phase 1Recruiting
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRichter Syndrome+1 more
PrincipalinvestigatorStart date: 2025-08-14
NCT06572618Phase 2Recruiting
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
Mantle Cell Lymphoma
PrincipalinvestigatorStart date: 2025-01-22
NCT05672355Phase 2Completed
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaCOVID-19 Infection
PrincipalinvestigatorStart date: 2023-08-01
NCT04783415Phase 2Active Not Recruiting
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
PrincipalinvestigatorStart date: 2021-03-26
NCT03961672Phase 2Active Not Recruiting
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more
PrincipalinvestigatorStart date: 2020-05-13
NCT03884998Phase 1Active Not Recruiting
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular Lymphoma+4 more
PrincipalinvestigatorStart date: 2019-07-10

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseIndolent Non-Hodgkin Lymphoma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Hagop Youssoufian, MD

Verastem, Inc.

Related
20 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularMarginal Zone Lymphoma
Similarity Score6%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Lymphoma, FollicularLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, Diffuse

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score6%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularLymphoma, Mantle-Cell
Similarity Score6%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score4%

Elena Pérez Ceballos, MD

Hospital Morales Meseguer

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score4%

Thomas E. Witzig, MD

Mayo Clinic

Related
12 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, Diffuse

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score4%

Carlos Montalbán Sanz, MD

Hospital Universitario Ramon y Cajal

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score4%

Eulogio Conde García, MD

Hospital Marqués de Valdecilla

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score4%

Arnon Nagler, MD

Chaim Sheba Medical Center

Related
12 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, Diffuse
Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (7)

Showing 7 of 7 trials

NCT07218510Phase 2PrincipalInvestigator

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Recruiting
NCT06735664Phase 1PrincipalInvestigator

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRichter Syndrome+1 more
Recruiting
NCT06572618Phase 2PrincipalInvestigator

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma
Recruiting
NCT05672355Phase 2PrincipalInvestigator

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic LeukemiaCOVID-19 Infection
Completed
NCT04783415Phase 2PrincipalInvestigator

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma
Active Not Recruiting
NCT03961672Phase 2PrincipalInvestigator

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more
Active Not Recruiting
NCT03884998Phase 1PrincipalInvestigator

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular Lymphoma+4 more
Active Not Recruiting

All 7 trials loaded